Obstetric complications and pregnancy-related venous thrombo - embolism

The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation

Daniela Tormene, Elvira Grandone, Valerio de Stefano, Alberto Tosetto, Gualtiero Palareti, Maurizio Margaglione, Giancarlo Castaman, Elena Rossi, Angela Ciminello, Leila Valdrè, Cristina Legnani, Giovanni Luca Tiscia, Valeria Bafunno, Sara Carraro, Francesco Rodeghiero, Paolo Simioni

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Whether the administration of low-molecular-weight heparin (LMWH) during pregnancy is effective in preventing obstetric complications and pregnancy-related venous thromboembolism (VTE) in women who are carriers of factor V Leiden (FVL) and/or prothrombin variant G20210A (PTm) is controversial. This observational study investigated the possible efficacy of pharmacological treatment with LMWH ± aspirin (ASA) in pregnancy outcomes in 1,011 pregnancies of 416 women with thrombophilia (FVL and/or PTm). Most patients were chosen on the basis of previous obstetrical complications (36%), or because of familial or personal history of venous/arterial thromboembolism (28% and 18%, respectively); 74 patients (18%) were incidentally identified. The outcome was evaluated according to the type of treatment and of the period of pregnancy when the treatment was started. After adjustment for observation before and after diagnosis of thrombophilia, previous miscarriages and VTE, parity, age and centre, we observed that LMWH had a protective effect on miscarriages (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.29-0.94) and VTE (OR 0.05, 95% CI 0.01-0.21). ASA appeared to have no effect on the prevention of obstetric complications and VTE. A nested analysis performed in 116 women with two or more obstetric complications confirmed that the highest number of live births was recorded in the group under LMWH prophylaxis (OR 0.19, 95% CI 0.05-0.75). These results suggest that LMWH prophylaxis reduces the risk of obstetric complications in carriers of FVL and/or PTm, particularly in those with previous obstetric events. Furthermore, LMWH prophylaxis reduces the risk of pregnancy-related VTE.

Original languageEnglish
Pages (from-to)477-484
Number of pages8
JournalThrombosis and Haemostasis
Volume107
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Pregnancy Complications
Low Molecular Weight Heparin
Venous Thromboembolism
Prothrombin
Embolism
Obstetrics
Mutation
Pregnancy
Odds Ratio
Spontaneous Abortion
Confidence Intervals
Thrombophilia
Live Birth
Pregnancy Outcome
Parity
Aspirin
Observational Studies
factor V Leiden
Observation
Pharmacology

Keywords

  • Lowmolecular-weight heparin
  • Obstetric complications
  • Pregnancy
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Obstetric complications and pregnancy-related venous thrombo - embolism : The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. / Tormene, Daniela; Grandone, Elvira; de Stefano, Valerio; Tosetto, Alberto; Palareti, Gualtiero; Margaglione, Maurizio; Castaman, Giancarlo; Rossi, Elena; Ciminello, Angela; Valdrè, Leila; Legnani, Cristina; Tiscia, Giovanni Luca; Bafunno, Valeria; Carraro, Sara; Rodeghiero, Francesco; Simioni, Paolo.

In: Thrombosis and Haemostasis, Vol. 107, No. 3, 03.2012, p. 477-484.

Research output: Contribution to journalArticle

Tormene, D, Grandone, E, de Stefano, V, Tosetto, A, Palareti, G, Margaglione, M, Castaman, G, Rossi, E, Ciminello, A, Valdrè, L, Legnani, C, Tiscia, GL, Bafunno, V, Carraro, S, Rodeghiero, F & Simioni, P 2012, 'Obstetric complications and pregnancy-related venous thrombo - embolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation', Thrombosis and Haemostasis, vol. 107, no. 3, pp. 477-484. https://doi.org/10.1160/TH11-07-0470
Tormene, Daniela ; Grandone, Elvira ; de Stefano, Valerio ; Tosetto, Alberto ; Palareti, Gualtiero ; Margaglione, Maurizio ; Castaman, Giancarlo ; Rossi, Elena ; Ciminello, Angela ; Valdrè, Leila ; Legnani, Cristina ; Tiscia, Giovanni Luca ; Bafunno, Valeria ; Carraro, Sara ; Rodeghiero, Francesco ; Simioni, Paolo. / Obstetric complications and pregnancy-related venous thrombo - embolism : The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. In: Thrombosis and Haemostasis. 2012 ; Vol. 107, No. 3. pp. 477-484.
@article{0893b086f79d407b9b2d9dce706b16f8,
title = "Obstetric complications and pregnancy-related venous thrombo - embolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation",
abstract = "Whether the administration of low-molecular-weight heparin (LMWH) during pregnancy is effective in preventing obstetric complications and pregnancy-related venous thromboembolism (VTE) in women who are carriers of factor V Leiden (FVL) and/or prothrombin variant G20210A (PTm) is controversial. This observational study investigated the possible efficacy of pharmacological treatment with LMWH ± aspirin (ASA) in pregnancy outcomes in 1,011 pregnancies of 416 women with thrombophilia (FVL and/or PTm). Most patients were chosen on the basis of previous obstetrical complications (36{\%}), or because of familial or personal history of venous/arterial thromboembolism (28{\%} and 18{\%}, respectively); 74 patients (18{\%}) were incidentally identified. The outcome was evaluated according to the type of treatment and of the period of pregnancy when the treatment was started. After adjustment for observation before and after diagnosis of thrombophilia, previous miscarriages and VTE, parity, age and centre, we observed that LMWH had a protective effect on miscarriages (odds ratio [OR] 0.52, 95{\%} confidence interval [CI] 0.29-0.94) and VTE (OR 0.05, 95{\%} CI 0.01-0.21). ASA appeared to have no effect on the prevention of obstetric complications and VTE. A nested analysis performed in 116 women with two or more obstetric complications confirmed that the highest number of live births was recorded in the group under LMWH prophylaxis (OR 0.19, 95{\%} CI 0.05-0.75). These results suggest that LMWH prophylaxis reduces the risk of obstetric complications in carriers of FVL and/or PTm, particularly in those with previous obstetric events. Furthermore, LMWH prophylaxis reduces the risk of pregnancy-related VTE.",
keywords = "Lowmolecular-weight heparin, Obstetric complications, Pregnancy, Venous thromboembolism",
author = "Daniela Tormene and Elvira Grandone and {de Stefano}, Valerio and Alberto Tosetto and Gualtiero Palareti and Maurizio Margaglione and Giancarlo Castaman and Elena Rossi and Angela Ciminello and Leila Valdr{\`e} and Cristina Legnani and Tiscia, {Giovanni Luca} and Valeria Bafunno and Sara Carraro and Francesco Rodeghiero and Paolo Simioni",
year = "2012",
month = "3",
doi = "10.1160/TH11-07-0470",
language = "English",
volume = "107",
pages = "477--484",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "3",

}

TY - JOUR

T1 - Obstetric complications and pregnancy-related venous thrombo - embolism

T2 - The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation

AU - Tormene, Daniela

AU - Grandone, Elvira

AU - de Stefano, Valerio

AU - Tosetto, Alberto

AU - Palareti, Gualtiero

AU - Margaglione, Maurizio

AU - Castaman, Giancarlo

AU - Rossi, Elena

AU - Ciminello, Angela

AU - Valdrè, Leila

AU - Legnani, Cristina

AU - Tiscia, Giovanni Luca

AU - Bafunno, Valeria

AU - Carraro, Sara

AU - Rodeghiero, Francesco

AU - Simioni, Paolo

PY - 2012/3

Y1 - 2012/3

N2 - Whether the administration of low-molecular-weight heparin (LMWH) during pregnancy is effective in preventing obstetric complications and pregnancy-related venous thromboembolism (VTE) in women who are carriers of factor V Leiden (FVL) and/or prothrombin variant G20210A (PTm) is controversial. This observational study investigated the possible efficacy of pharmacological treatment with LMWH ± aspirin (ASA) in pregnancy outcomes in 1,011 pregnancies of 416 women with thrombophilia (FVL and/or PTm). Most patients were chosen on the basis of previous obstetrical complications (36%), or because of familial or personal history of venous/arterial thromboembolism (28% and 18%, respectively); 74 patients (18%) were incidentally identified. The outcome was evaluated according to the type of treatment and of the period of pregnancy when the treatment was started. After adjustment for observation before and after diagnosis of thrombophilia, previous miscarriages and VTE, parity, age and centre, we observed that LMWH had a protective effect on miscarriages (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.29-0.94) and VTE (OR 0.05, 95% CI 0.01-0.21). ASA appeared to have no effect on the prevention of obstetric complications and VTE. A nested analysis performed in 116 women with two or more obstetric complications confirmed that the highest number of live births was recorded in the group under LMWH prophylaxis (OR 0.19, 95% CI 0.05-0.75). These results suggest that LMWH prophylaxis reduces the risk of obstetric complications in carriers of FVL and/or PTm, particularly in those with previous obstetric events. Furthermore, LMWH prophylaxis reduces the risk of pregnancy-related VTE.

AB - Whether the administration of low-molecular-weight heparin (LMWH) during pregnancy is effective in preventing obstetric complications and pregnancy-related venous thromboembolism (VTE) in women who are carriers of factor V Leiden (FVL) and/or prothrombin variant G20210A (PTm) is controversial. This observational study investigated the possible efficacy of pharmacological treatment with LMWH ± aspirin (ASA) in pregnancy outcomes in 1,011 pregnancies of 416 women with thrombophilia (FVL and/or PTm). Most patients were chosen on the basis of previous obstetrical complications (36%), or because of familial or personal history of venous/arterial thromboembolism (28% and 18%, respectively); 74 patients (18%) were incidentally identified. The outcome was evaluated according to the type of treatment and of the period of pregnancy when the treatment was started. After adjustment for observation before and after diagnosis of thrombophilia, previous miscarriages and VTE, parity, age and centre, we observed that LMWH had a protective effect on miscarriages (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.29-0.94) and VTE (OR 0.05, 95% CI 0.01-0.21). ASA appeared to have no effect on the prevention of obstetric complications and VTE. A nested analysis performed in 116 women with two or more obstetric complications confirmed that the highest number of live births was recorded in the group under LMWH prophylaxis (OR 0.19, 95% CI 0.05-0.75). These results suggest that LMWH prophylaxis reduces the risk of obstetric complications in carriers of FVL and/or PTm, particularly in those with previous obstetric events. Furthermore, LMWH prophylaxis reduces the risk of pregnancy-related VTE.

KW - Lowmolecular-weight heparin

KW - Obstetric complications

KW - Pregnancy

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84857732644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857732644&partnerID=8YFLogxK

U2 - 10.1160/TH11-07-0470

DO - 10.1160/TH11-07-0470

M3 - Article

VL - 107

SP - 477

EP - 484

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 3

ER -